Cogent Biosciences, Inc. (COGT)

The past six months have seen several significant events impacting Cogent Biosciences' stock price. In July 2025, Cogent Biosciences reported positive top-line data from the SUMMIT trial and new options for January 2026 expiration began trading. In November 2025, the company reported positive results from the Bezuclastinib PEAK Phase 3 Trial, an offering of equity and convertible notes coincided with a stock gain, and UBS and Wedbush upgraded Cogent Biosciences' rating. In December 2025, Cogent Biosciences announced positive top-line results from the APEX Trial, presented full SUMMIT results at ASH, and submitted an NDA for bezuclastinib in NonAdvSM to the FDA. In January 2026, Raymond James and UBS initiated coverage with a "Buy" rating, H.C. Wainwright reaffirmed a "Buy" rating and increased its price target, and the company highlighted key 2026 milestones. Despite these positive developments, the stock experienced a decline after several executives sold significant shares. Overall, Cogent Biosciences' stock has delivered an extraordinary return over the past year, though it has experienced volatility in the last three months.

Traditional demand seasonality is not a primary factor for Cogent Biosciences, as it is a clinical-stage biotechnology company with no significant product revenue reported to date. The demand for its precision therapies will likely be driven by medical need for genetically defined diseases, rather than seasonal fluctuations. An analysis of COGT's seasonal chart suggests a "Buy Date" of May 16 and a "Sell Date" of August 22, which has historically resulted in a geometric average return of 53.88% above the S&P 500 Total Return Index over the past six years.

Cogent Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases, operating within the Healthcare sector and Biotechnology industry, specifically Pharmaceutical Preparations. Their lead product candidate is bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trials, targeting mutations within the KIT receptor tyrosine kinase. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 (FGFR2) inhibitor, currently in Phase 1 trial. Cogent Biosciences is advancing a portfolio of novel targeted therapies aimed at mutations in ErbB2, PI3Kα, KRAS, and JAK2 V617F.

Cogent Biosciences is headquartered in Waltham, Massachusetts, United States. In October 2025, the company relocated its corporate headquarters to 180 CityPoint in Waltham, MA. The company also maintains offices in Colorado, US.

Cogent Biosciences' brand reputation has been largely positive, driven by clinical advancements and strong analyst interest. The company received Breakthrough Therapy Designation for bezuclastinib and positive top-line results from the SUMMIT, PEAK, and APEX trials. The submission of an NDA for bezuclastinib in NonAdvSM further highlights its progress. Analysts generally hold a "Moderate Buy" consensus rating for COGT. The company's strong financial position is expected to fund operations well into 2028. However, the company remains unprofitable, and InvestingPro's Fair Value assessment suggests the stock may be overvalued. A decline in stock value occurred after several executives sold significant shares, impacting investor sentiment. Shareholders have also experienced substantial dilution in the past year, and the stock's weekly volatility has increased. Additionally, an increase in short interest indicates a decrease in investor sentiment.

Cogent Biosciences has a substantial institutional ownership base, with major holders including Fmr Llc, BlackRock, Inc., and Deerfield Management Company, L.P. Fairmount Funds Management LLC is a significant individual shareholder, owning 9.00 million shares, representing 6.32% of the company. Individual insider ownership accounts for 0.573% of the shares outstanding. While insider sentiment is generally positive, there has been more insider selling than buying in high-impact open-market transactions.